A Study Evaluating AHB-137 in Healthy Participants and Participants With Chronic Hepatitis B
Status:
Not yet recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
AHB-137 subcutaneous injection in healthy volunteers and in chronic hepatitis B (CHB)
patients after single and multiple doses. In addition, the study will evaluate the antiviral
efficacy of AHB-137 in CHB patients following a multiple dosing regimen.